OBJECTIVE: Most patients with epithelial ovarian cancer who are alive at 5 years have active disease. Thus, 10-year survival rather than 5-year survival may be a more appropriate endpoint. Relative survival adjusts for the general survival of the United States population for that race, sex, age, and date at which the diagnosis was coded. Our objective was to estimate relative survival in epithelial ovarian cancer over the course of 10 years. METHODS: Using the Surveillance, Epidemiology and End Results 1995-2007 database, epithelial ovarian cancer cases were identified. Using the actuarial life table method, relative survival over the course of 10 years was calculated, stratified by stage, classification of residence, surgery as the first course of treatment, race, and age. RESULTS: There were 40,692 patients who met inclusion criteria. The overall relative survival was 65%, 44%, and 36% at 2, 5, and 10 years, respectively. The slope of decline in relative survival was reduced for years 5-10 as compared with years 1-5 after diagnosis. Relative survival at 5 years was 89%, 70%, 36%, and 17%, and at 10 years relative survival was 84%, 59%, 23%, and 8% for stages I, II III, and IV, respectively. At all stages, patients with nonsurgical primary treatment and those with advanced age had reduced relative survival. CONCLUSIONS: The 10-year relative survival for stage III is higher than expected. This information provides the physician and the patient with more accurate prognostic information.
OBJECTIVE: Most patients with epithelial ovarian cancer who are alive at 5 years have active disease. Thus, 10-year survival rather than 5-year survival may be a more appropriate endpoint. Relative survival adjusts for the general survival of the United States population for that race, sex, age, and date at which the diagnosis was coded. Our objective was to estimate relative survival in epithelial ovarian cancer over the course of 10 years. METHODS: Using the Surveillance, Epidemiology and End Results 1995-2007 database, epithelial ovarian cancer cases were identified. Using the actuarial life table method, relative survival over the course of 10 years was calculated, stratified by stage, classification of residence, surgery as the first course of treatment, race, and age. RESULTS: There were 40,692 patients who met inclusion criteria. The overall relative survival was 65%, 44%, and 36% at 2, 5, and 10 years, respectively. The slope of decline in relative survival was reduced for years 5-10 as compared with years 1-5 after diagnosis. Relative survival at 5 years was 89%, 70%, 36%, and 17%, and at 10 years relative survival was 84%, 59%, 23%, and 8% for stages I, II III, and IV, respectively. At all stages, patients with nonsurgical primary treatment and those with advanced age had reduced relative survival. CONCLUSIONS: The 10-year relative survival for stage III is higher than expected. This information provides the physician and the patient with more accurate prognostic information.
Authors: Cynthia A Thomson; Tracy E Crane; Austin Miller; David O Garcia; Karen Basen-Engquist; David S Alberts Journal: Contemp Clin Trials Date: 2016-07-06 Impact factor: 2.226
Authors: Carol Aghajanian; Barbara Goff; Lawrence R Nycum; Yan V Wang; Amreen Husain; Stephanie V Blank Journal: Gynecol Oncol Date: 2015-08-10 Impact factor: 5.482
Authors: Jeff Hirst; Harsh B Pathak; Stephen Hyter; Ziyan Y Pessetto; Thuc Ly; Stefan Graw; Devin C Koestler; Adam J Krieg; Katherine F Roby; Andrew K Godwin Journal: Cancer Res Date: 2018-06-11 Impact factor: 12.701
Authors: Joanne O'Dwyer; Roisin E O'Cearbhaill; Robert Wylie; Saoirse O'Mahony; Michael O'Dwyer; Garry P Duffy; Eimear B Dolan Journal: Adv Ther (Weinh) Date: 2020-08-16
Authors: Bastian Czogalla; Christina Kuhn; Sabine Heublein; Elisa Schmöckel; Doris Mayr; Thomas Kolben; Fabian Trillsch; Alexander Burges; Sven Mahner; Udo Jeschke; Anna Hester Journal: J Cancer Res Clin Oncol Date: 2019-09-04 Impact factor: 4.553
Authors: Chanhee Han; Stefania Bellone; Eric R Siegel; Gary Altwerger; Gulden Menderes; Elena Bonazzoli; Tomomi Egawa-Takata; Francesca Pettinella; Anna Bianchi; Francesco Riccio; Luca Zammataro; Ghanshyam Yadav; Jarrod A Marto; Marie-France Penet; Douglas A Levine; Ronny Drapkin; Abhijit Patel; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Gloria S Huang; Masoud Azodi; Peter E Schwartz; Alessandro D Santin Journal: Gynecol Oncol Date: 2018-03-21 Impact factor: 5.482